Artelo Biosciences (ARTL) Non-Current Assets (2017 - 2025)
Artelo Biosciences (ARTL) posted quarterly Non-Current Assets of $2.1 million for Q4 2025, down 1.63% year-over-year from $2.1 million in Q4 2024, and down 13.69% quarter-over-quarter from $2.4 million in Q3 2025.
Artelo Biosciences (ARTL) Non-Current Assets (2017 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Non-Current Assets for 9 consecutive years, with $2.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 1.63% year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $8.8 million (up 2.18% YoY), while the FY2025 annual figure was $2.1 million, down 1.63% from the prior year.
- Non-Current Assets retreated to $2.1 million in Q4 2025 per ARTL's latest filing, from $2.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.6 million in Q4 2021 and bottomed at $2.0 million in Q2 2021.
- Historically, Non-Current Assets has averaged $2.2 million across 5 years, with a median of $2.1 million in 2022.
- Annual changes were most pronounced in 2021 — Non-Current Assets soared 78.91% — and 2024, when it retreated 5.14%.
- Artelo Biosciences' Non-Current Assets stood at $3.6 million in 2021, then sank by 42.4% to $2.1 million in 2022, then dropped by 1.86% to $2.1 million in 2023, then climbed by 3.78% to $2.1 million in 2024, then slipped by 1.63% to $2.1 million in 2025.
- Business Quant data shows ARTL's Non-Current Assets at $2.1 million in Q4 2025, $2.4 million in Q3 2025, and $2.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Artelo Biosciences | 113,113.52 | -486,886.48 | - | 2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 2.44 Mn |
| Jun 30, 2025 | 2.12 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 2.14 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.17 Mn |
| Dec 31, 2023 | 2.06 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 2.11 Mn |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Nov 30, 2021 | 3.65 Mn |
| Aug 31, 2021 | 2.32 Mn |
| May 31, 2021 | 2.04 Mn |
| Feb 28, 2021 | 2.04 Mn |